Guenter Fingerle-Rowson

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

C.‐M. Wendtner, Matthias Ritgen, C D Schweighofer et al. · Leukemia · 2004 · 268 citations

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukemia +7

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, Guenter Fingerle-Rowson, Anna Maria Fink et al. · Blood · 2008 · 134 citations

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klánová, Laurie H. Sehn, Isabelle Bence‐Bruckler et al. · Blood · 2019 · 124 citations · Full text

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

Sebastian Böttcher, Stephan Stilgenbauer, Robert Busch et al. · Leukemia · 2009 · 104 citations

Lymphoid Neoplasia, Autoimmune Disease, Mrd Flow +8